The market doesn't appear to be overly excited about it ?
Perhaps due to the ambiguity of the announcement - no specific product mentioned and no upfront payment ?
Initial project is for the development of DEP® conjugates for an anti-infective drug, with an ability to add additional programs in other therapeutic areas.
Does anybody else think this is perhaps 'treading' on AstraZeneca's toes ? Or at the very least signing away AstraZeneca's rights in China / Asia for conjugates given our AZD0466 (DEP® Bcl2/xL conjugate) deal ? @Ima Scientist - thoughts ?
Agree @gaucau ... not overly excited about the "China" aspect .... especially given their reputation regarding accusations of patent copying / stealing - just sayin' ... have we done a deal with the devil ?
Ann: Starpharma signs new DEP partnership with Chase Sun, page-7
-
- There are more pages in this discussion • 89 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.001(1.02%) |
Mkt cap ! $40.48M | |||
| Open | High | Low | Value | Volume |
| 9.6¢ | 10.0¢ | 9.6¢ | $5.703K | 58.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 20000 | 1 |
View Market Depth
| Last trade - 15.41pm 11/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |